 Corcept Therapeutics Incorporated NASDAQ: CORT has announced preliminary results from its Phase 3 RELIANT trial of relacorilant for metastatic pancreatic cancer. The trial evaluated relacorilant plus nab-paclitaxel in pancreatic cancer patients who had relapsed following at least two prior lines of therapy. 